Companies Particle Health

Particle Health

New York

40 Total Employees

18 Product + Tech Employees

Year Founded: 2018

View Website

Particle Health Company Growth, Stability & Outlook

Updated on September 16, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Particle Health and has not been reviewed or approved by Particle Health.

What's the stability & growth outlook for Particle Health?

Strengths in capital support, product cadence, and expanding network reach are accompanied by partnership turbulence tied to 2024 exchange disputes and continuing litigation. Together, these dynamics suggest ongoing platform and market advancement tempered by dependency risks that could influence the durability and pace of growth.

Key Insight for Candidates

Defining tradeoff: Lean, product‑led scaling via national networks, but high platform risk from incumbent‑controlled rails (e.g., Epic/Carequality disputes). For candidates: expect a small team shipping fast with high ownership, amid occasional access disruptions and legal overhang that can abruptly reshape priorities and partnerships.

Evidence in Action

Capital-Efficient Headcount Model — The "11–50 employee band (2026)" and flat hiring trend signal a capital-efficient scaling approach prioritizing product, revenue, and network growth over rapid staff increases. Employees operate lean, take broad ownership, and optimize for shipping velocity and measurable customer impact per person.
Funding-Backed Shipping Cadence — The "Series B extension ($10M, December 2024)" and ongoing Signal/Insights releases (2024–2026) codify a roadmap that continues shipping through market turbulence and litigation. Employees plan confidently against funded horizons, prioritizing incremental value delivery and resilience over headline headcount growth.

Positive Themes About Particle Health

Investor Backing & Capital Strength: Fresh capital in late 2024 (a $10M Series B extension on top of the 2022 Series B) underscores continued support and runway for growth. These resources are described as enabling ongoing product and commercial investment.
Product Line Growth: New offerings and updates since 2024—such as a Patient Monitoring Solution and the Signal real-time alerting suite, with documentation and features continuing into 2025–2026—indicate sustained roadmap velocity. The company is still shipping features through 2026.
Market Expansion: Scale indicators and positioning have trended up, from coverage claims of 270M+ patients (2022) to 320M+ (2025) while targeting payers, providers, and platforms. Broader connectivity via Carequality, CommonWell, eHealth Exchange, public HIEs, and a Surescripts certification (Feb 2025) expand usable data sources.

Considerations About Particle Health

Deteriorating Partnerships: A 2024 interoperability dispute—during which Epic paused responses to some Particle customer queries—and ongoing Epic–Particle litigation introduce relationship friction and platform risk. Although Carequality later reported a resolution with policy updates, case outcomes could still affect momentum and partnerships.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.